[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target]

Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23.

[Article in Spanish]

Authors

Carlos Guijarro¹, Luis Miguel Ruilope²

Affiliations

¹ Unidad de Medicina Interna, Consulta de Riesgo Vascular, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Madrid, España. Electronic address: cguijarro@fhalcorcon.es.
² Instituto de Investigación, Unidad de Hipertensión, Hospital Universitario 12 de Octubre, Madrid, España.

PMID: 26004275
DOI: 10.1016/j.medcli.2015.04.007

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Biomarkers / metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / drug therapy
Hypercholesterolemia / genetics
Hypercholesterolemia / metabolism*
Hyperlipoproteinemias / drug therapy
Hyperlipoproteinemias / genetics
Hyperlipoproteinemias / metabolism*
Hypolipidemic Agents / therapeutic use*
Lipoproteins, LDL / genetics
Lipoproteins, LDL / metabolism*
Proprotein Convertase 9
Proprotein Convertases / antagonists & inhibitors
Proprotein Convertases / genetics
Proprotein Convertases / metabolism*
Risk Reduction Behavior
Serine Endopeptidases / genetics
Serine Endopeptidases / metabolism*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipoproteins, LDL
PCSK9 protein, human
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases
evolocumab
alirocumab